Skip to main content

Table 3 Pre- and postprocedural regimens, partial or full recapture of the device, resizing of the device

From: Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation

 Device for transseptal puncture (n= / %)Preprocedural antiplatelet regimens or OAC (VKA, NOAC);
(n= / %)
Regular antiplatelet or OAC regimens post-LAAC procedurePartial recapture of the device
(n= / %)
Full recapture of the device
(n= / %)
Resizing of the device
(n= / %)
Chen et al. (2019) [21]N/AVKA: n = 13 / 56.7%;
NOAC: n = 17 / 1.7%
OAC: n = 1 / 3.3%
DAPT for 6 months, followed by lifetime ASS: n = 29 / 96.7%
14 / 46.7%N/A0
Feng et al. (2019) [22]Brockenbrough needle and SL1 transseptal sheath (St. Jude Medical)N/ADAPT for 3 months, followed by lifetime ASSN/AN/A1 / 5.9%
Reinsch et al. (2018) [19]Brockenbrough needle and SL1 transseptal sheath (St. Jude Medical)N/ADAPT for 6 months, followed by lifetime ASS11 / 27%1 / 9%1 / 9%
Park et al. (2018) [18]N/AASS: n = 46 / 78%;
Clopidogrel: n = 49 / 82%;
heparin: n = 14 / 23%;
VKA: n = 2 / 3.3%;
NOAC: n = 1 / 1.7%
DAPT for 3 months21 / 38%9 / 14%3 / 5%
Kleinecke et al. (2018) [17]Brockenbrough needle (St. Jude Medical)N/AN/AN/A20 / 100%0
Cruz-Gonzalez et al. (2018) [20]N/AN/ADAPT: n = 3 / 43%
SAPT: n = 1 / 14%
NOAC: n = 2 / 28%
LMWH: n = 1 / 14%
N/AN/AN/A
Chen et al. (2018) [9]N/AN/ADAPT: n = 29 / 96.7%N/A1 / 3.3%N/A
Zhou et al. (2017) [16]N/AVKA: n = 21 / 100%N/AN/AN/AN/A
Huang et al. (2017) [15]N/AN/AN/AN/AN/AN/A
Jie et al. (2016) [14]Brockenbrough needle with SL1 transseptal sheath (St. Jude Medical)ASS: n = 13 / 18%
Clopidogrel: n = 5 / 7%
VKA: n = 18 / 25%
N/AN/AN/AN/A
Total /
Overall mean
Brockenbrough needle, mostly used with the SL1 transseptal sheathVKA or NOAC:
n = 72/165 = 43.6%
Other:
n = 93/165 = 56.4%
DAPT in
n = 150/155 = 96.8%
46 / 45.5%31 / 25.6%5 / 3.6%
  1. Abbreviations
  2. DAPT Dual antiplatelet therapy (aspirin plus clopidogrel)
  3. LMWH Low-molecular weight heparin
  4. N/A Not available
  5. NOAC New oral anticoagulants
  6. OAC Oral anticoagulation
  7. SAPT Single antiplatelet therapy (aspirin or clopidogrel)
  8. VKA Vitamin K antagonists